459 related articles for article (PubMed ID: 15738539)
1. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
2. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
5. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
6. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Hillmen P
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
Hillmen P; Skotnicki AB; Robak T; Jaksic B; Dmoszynska A; Wu J; Sirard C; Mayer J
J Clin Oncol; 2007 Dec; 25(35):5616-23. PubMed ID: 17984186
[TBL] [Abstract][Full Text] [Related]
8. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract][Full Text] [Related]
9. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
Schweighofer CD; Ritgen M; Eichhorst BF; Busch R; Abenhardt W; Kneba M; Hallek M; Wendtner CM
Br J Haematol; 2009 Jan; 144(1):95-8. PubMed ID: 19016732
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
12. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
14. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
17. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Varghese AM; Howard DR; Pocock C; Rawstron AC; Follows G; McCarthy H; Dearden C; Fegan C; Milligan D; Smith AF; Gregory W; Hillmen P;
Br J Haematol; 2017 Feb; 176(4):573-582. PubMed ID: 28032335
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Ferrajoli A; O'Brien SM; Cortes JE; Giles FJ; Thomas DA; Faderl S; Kurzrock R; Lerner S; Kontoyiannis DP; Keating MJ
Cancer; 2003 Aug; 98(4):773-8. PubMed ID: 12910522
[TBL] [Abstract][Full Text] [Related]
19. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]